Cover Image
市場調查報告書

過敏性鼻炎治療藥的全球市場:2016年∼2020年

Global Allergic Rhinitis Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 352221
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
過敏性鼻炎治療藥的全球市場:2016年∼2020年 Global Allergic Rhinitis Drugs Market 2016-2020
出版日期: 2016年02月10日 內容資訊: 英文 90 Pages
簡介

全球過敏性鼻炎治療藥市場預測在2016年∼2020年間將以年複合成長率 (CAGR) 0.95%的速度成長。

本報告提供全球過敏性鼻炎治療藥市場相關調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 概要:過敏性鼻炎

  • 關於疾病
  • 過敏性鼻炎的分類
  • 原因
  • 徵兆·症狀
  • 危險因素
  • 診斷·檢驗
  • 治療
  • 流行病學
  • 經濟負擔和QOL的影響

第6章 開發平台分析

  • 開發平台候補相關資訊
  • 過敏性鼻炎相關臨床實驗資訊

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:藥物類別

  • 抗組織胺藥物
  • 鼻腔內皮質類固醇
  • 免疫療法

第9章 市場區隔:各給藥途徑

  • 口服
  • 非口服
  • 鼻腔內

第10章 市場區隔:各劑型

  • 固體
  • 液體

第11章 地理區分

  • 各地區
  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第12章 推動市場要素

第13章 推動因素的影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • AstraZeneca
  • GlaxoSmithKline
  • Meda Pharmaceuticals
  • Merck
  • Sanofi
  • UCB
  • 其他卓越供應商

第18章 附錄

第19章 關於Technavio

圖表

目錄
Product Code: IRTNTR8279

About Allergic Rhinitis Drugs

Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.

Technavio's analysts forecast the global allergic rhinitis market to grow at a CAGR of 0.95% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global allergic rhinitis drugs market for the period 2016-2020. To calculate the market size, it considers revenue generated from the sales of prescription and off-label drugs used to treat allergic rhinitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • Europe

Technavio's report, Global Allergic Rhinitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • GlaxoSmithKline
  • Meda Pharmaceuticals
  • Merck
  • Sanofi
  • UCB

Other Prominent Vendors

  • Adamis Pharmaceuticals
  • Alcon
  • Alergo Pharma
  • ALK-Abello
  • Allergy Therapeutics
  • Almirall
  • Ampio
  • Anergis
  • Apotex
  • Ares Life Sciences
  • Array BioPharma
  • Aspen Pharmacare
  • Atopix Therapeutics
  • Barr Laboratories
  • Belcher Pharmaceuticals
  • Circassia Pharmaceuticals
  • Dainippon Sumitomo
  • DBV Technologies
  • Dr Reddy's Laboratories
  • Eddingpharm
  • Genentech
  • Greer Laboratories
  • Hanmi Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Intas Pharmaceuticals
  • Kyowa Hakko
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Nektar Therapeutics
  • Novartis
  • Nuvo Research
  • Nycomed
  • Omega Pharma
  • Ono Pharmaceuticals
  • Pfizer
  • Revance Therapeutics
  • Roxane Laboratories (Boehringer Ingelheim)
  • Shionogi
  • Stallergenes
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical
  • Teva Pharmaceuticals
  • Verona Pharma
  • VentiRx Pharmaceuticals

Market driver

  • Increased prevalence of allergic rhinitis
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries and competition from generic drugs
  • For a full, detailed list, view our report

Market trend

  • Increased R&D
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview: Allergic rhinitis

  • Understanding the disease
  • Classification of allergic rhinitis
  • Causes
  • Signs and symptoms
  • Risk factors
  • Diagnosis and testing
  • Treatment
  • Epidemiology
  • Economic burden and impact on quality of life

PART 06: Pipeline analysis

  • Information on pipeline candidates
  • Clinical trial information of allergic rhinitis

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation based on class of drugs

  • Antihistamines
  • Intranasal corticosteroids
  • Immunotherapies
  • Global antihistamines drugs market
  • Global intranasal corticosteroids drugs market
  • Global immunotherapies drugs market

PART 09: Market segmentation by route of administration

  • Oral
  • Parenteral
  • Intranasal

PART 10: Market segmentation by dosage form

  • Solid
  • Liquid

PART 11: Geographical segmentation

  • Global allergic rhinitis drugs market by geography 2015-2020
  • Allergic rhinitis drugs market in Americas
  • Allergic rhinitis drugs market in EMEA
  • Allergic rhinitis drugs market in APAC

PART 12: Market drivers

  • Increased prevalence of allergic rhinitis
  • Rise in awareness about allergic rhinitis
  • High usage of tobacco
  • Presence of high unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges

  • Increased preference for CAM
  • Patent expiries and competition from generic drugs
  • Adverse effects of drugs
  • Poor patient adherence

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Self-medication using OTC products
  • Increased R&D
  • Intense competition
  • Strategic alliances

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • AstraZeneca
  • GlaxoSmithKline
  • Meda Pharmaceuticals
  • Merck
  • Sanofi
  • UCB
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of allergic rhinitis
  • Exhibit 03: Risk factors associated with allergic rhinitis
  • Exhibit 04: Major diagnostic procedures for allergic rhinitis
  • Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis
  • Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
  • Exhibit 07: Non-pharmacological therapies for allergic rhinitis
  • Exhibit 08: Examples of non-pharmacological therapies
  • Exhibit 09: Treatment algorithm of allergic rhinitis
  • Exhibit 10: Prevalence of allergic rhinitis in China
  • Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio
  • Exhibit 12: Allergic rhinitis clinical trials by development phase 2015
  • Exhibit 13: Allergic rhinitis clinical trials by trial status 2015
  • Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions)
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Global allergic rhinitis market based on class of drugs
  • Exhibit 17: Examples of prescription and OTC intranasal corticosteroids
  • Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015
  • Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions)
  • Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions)
  • Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions)
  • Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions)
  • Exhibit 23: Global allergic rhinitis drugs market by route of administration
  • Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form
  • Exhibit 25: Global allergic rhinitis drugs market by geography 2015
  • Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 30: Drivers of global allergic rhinitis drugs market
  • Exhibit 31: Impact of drivers
  • Exhibit 32: Challenges of global allergic rhinitis drugs market
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Trends of global allergic rhinitis drugs market
  • Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US
  • Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015
  • Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions)
  • Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
  • Exhibit 41: AstraZeneca: Key takeaways
  • Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
  • Exhibit 46: GlaxoSmithKline: Key takeaways
  • Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014
  • Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 50: Meda Pharmaceuticals: Top-selling drugs
  • Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions)
  • Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions)
  • Exhibit 53: Meda Pharmaceuticals: Key takeaways
  • Exhibit 54: Merck: Business segmentation by revenue 2014
  • Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 56: Merck: Geographical segmentation by revenue 2014
  • Exhibit 57: Merck: Top-selling drugs
  • Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)
  • Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)
  • Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)
  • Exhibit 61: Merck: Key takeaways
  • Exhibit 62: Sanofi: Business segmentation by revenue 2014
  • Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 64: Sanofi: Geographical segmentation by revenue 2014
  • Exhibit 65: Sanofi: Top-selling drugs
  • Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions)
  • Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions)
  • Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions)
  • Exhibit 69: Sanofi: Key takeaways
  • Exhibit 70: UCB: Product segmentation by revenue 2014
  • Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 72: UCB: Geographical segmentation by revenue 2014
  • Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions)
  • Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions)
  • Exhibit 75: UCB: Key takeaways
Back to Top